# CanadaBuys #W6369-27-A062

Canadian DND procurement of Ca-DTPA ampoules for radiological exposure treatment

**Posted:** November 10, 2026
**Respond By:** November 25, 2026
**Identifier:** W6369-27-A062
**NAICS:** 325412, 424210

Canada’s Department of National Defence is seeking a radiological-contamination treatment medicine for Canadian Armed Forces health services.
- **Buyer:** Government of Canada, Department of National Defence (DND), through the Strategic Medical Countermeasures Program, on behalf of the Canadian Forces Health Services Group.
- **OEM:** **Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG**, identified as the only currently known capable supplier.
- **Requested product:** 750 Calcium Trisodium Pentetate (Ca-DTPA) ampoules, with an option for up to 500 additional ampoules; no part number is specified.
  - Each ampoule must contain a sterile intravenous solution of 1,000–1,055 mg Ca-DTPA in 5 mL.
  - Intended to treat known or suspected internal contamination from radiological agents, including transuranic elements.
- **Key requirements:** Valid authorization from an accepted regulator; documentation supporting the active ingredient and treatment indication; at least 36 months of shelf life backed by stability data; and compliance with operational, quality, packaging, storage, and labelling requirements.
- **Supply timing:** Three firm delivery tranches of 250 ampoules each over the first three years; the option for up to 500 more may be exercised during the contract term. Other suppliers may demonstrate their ability to meet all requirements.

### Description

The Department of National Defence seeks 750 Calcium Trisodium Pentetate (Ca-DTPA) ampoules to treat Canadian Armed Forces personnel who may have been exposed to radiological agents, with an option for up to 500 additional ampoules. The product must be a sterile intravenous solution containing 1,000–1,055 mg of Ca-DTPA in a 5 mL ampoule and meet specified authorization, quality, packaging, storage, and shelf-life requirements. Deliveries include 250 ampoules by March 1, 2027, followed by 250 in each of fiscal years 2027–2028 and 2028–2029. This Advance Contract Award Notice identifies Heyl Chem.-pharm. Fabrik GmbH & Co. KG as the only currently known supplier; other suppliers may submit a Statement of Capabilities by the closing date.

[View original listing](https://canadabuys.canada.ca/en/tender-opportunities/tender-notice/cb-141-88756202)